EUCTR2007-001105-13-PL进行中（未招募）不适用
A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female patients =18 years with locally advanced, inflammatory or early
- •stage, unilateral and histologically confirmed invasive breast cancer.
- •2. Primary tumor >2cm in diameter.
- •3. HER2 positive confirmed by a central laboratory. Tumors must be HER2+++
- •by IHC or FISH/CISH + (FISH/CISH mandatory for HER2 ++ tumors).
- •4. Availability of FFPE tissue for central confirmation of HER2 eligibility (FFPE
- •tumor tissue will subsequently be used for assessing status of biomarkers).
- •5. Baseline LVEF of = 55% (measured by echocardiogram or MUGA).
- •6. Performance status ECOG Scale = 1.
- •7. At least 4 weeks since major unrelated surgery, with full recovery.
- •8. A negative pregnancy test must be available for pre-menopausal women and for
- •women less than 2 years after the onset of menopause.
- •9. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Metastatic disease (Stage IV) or bilateral breast cancer.
- •2. Previous anticancer therapy or radiotherapy for any malignancy.
- •3. Other malignancy, except for carcinoma in situ of the cervix or basal cell
- •4. Inadequate bone marrow function (e.g. Absolute Neutrophil Count (ANC)
- •<1.5 x 1,000,000,000/L, Platelet count < 100 x 1,000,000,000/L and
- •Hb < 9 g/dL ).
- •5. Impaired liver function: (e.g. serum [total] bilirubin > 1.25 x ULN (with the
- •exception of Gilbert’s syndrome), AST, ALT > 1.25 x ULN, albumin < 25 g/L
- •6. Inadequate renal function, serum creatinine >1.5 x ULN.
- •7. Uncontrolled hypertension (systolic > 150 and/or diastolic > 100), unstable
- •angina, CHF of any NYHA classification, serious cardiac arrhythmia requiring
- •treatment (exception, atrial fibrillation, paroxysmal supraventricular tachycardia),
- •history of myocardial. infarction within 6 months of enrollment, or LVEF < 55%.
- •8. Dyspnea at rest or other diseases which require continuous oxygen therapy.
- •9. Severe uncontrolled systemic disease (e.g. hypertension, clinically significant
- •cardiovascular, pulmonary, metabolic, wound-healing, ulcer, or bone fracture).
- •10. Subjects with insulin-dependent diabetes.
- •11. Pregnant and/or lactating women.
- •12. Subjects with reproductive potential not willing to use highly effective nonhormonal method of contraception or two effective forms of non-hormonal contraception. Contraception use must continue for the duration of study treatment and for at least 6 months post discontinuation of study treatment. For details please see Section 7.2.4.
- •13. Received any investigational treatment within 4 weeks of study start.
- •14. Subjects with known infection with HIV, HBV, HCV.
- •15. Known hypersensitivity to any of the study drugs or excipients.
- •16. Subjects assessed by the investigator to be unable or unwilling to comply with
- •the requirements of the protocol.
研究者
相似试验
进行中（未招募）
1 期
A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.EUCTR2007-001105-13-GBF. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR417
进行中（未招募）
不适用
A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. - NEOSPHEREocally advanced, inflammatory or early stage HER2 positive breast cancer.MedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10006200Term: Breast cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10006201Term: Breast cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerEUCTR2007-001105-13-ATF. Hoffmann-La Roche Ltd400
进行中（未招募）
不适用
A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.ocally advanced, inflammatory or early stage HER2 positive breast cancer.MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-001105-13-ITHoffman - La Roche400
进行中（未招募）
不适用
A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancerEUCTR2007-001105-13-SEF. Hoffmann-La Roche Ltd400
进行中（未招募）
1 期
A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancerocally advanced, inflammatory or early stage HER2 positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012019-17-DEF. Hoffmann-La Roche Ltd.225